Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Int J Urol. 2024 Sep;31(9):975-985. doi: 10.1111/iju.15499. Epub 2024 Jun 1.
To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Among the 198 questions discussed at the APCCC 2022, the APCCC-JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high-level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on-site using a web-based system. The results were compared with those of APCCC 2022.
This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment.
APCCC-JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context-specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision-making in the management of advanced prostate cancer.
评估和比较日本泌尿科医生与 2022 年高级前列腺癌共识会议（APCCC）全球专家组的投票结果。
在 APCCC 2022 讨论的 198 个问题中，APCCC-JAPAN 2023 重点关注了 14 个与高级前列腺癌管理相关的关键问题，这些问题基于与日本队列的相关性，缺乏基于高级证据的管理。一个由 6 名前列腺癌专家组成的小组回答了这 14 个问题，并向使用基于网络的系统现场投票的日本泌尿科医生介绍了最新证据。结果与 APCCC 2022 进行了比较。
本研究发现，日本泌尿科医生和全球专家组在几个与高级前列腺癌管理相关的关键问题上的投票结果存在显著差异。这些差异体现在治疗偏好、监测策略以及特定临床情况下的治疗选择方面。这些发现强调了需要根据日本医疗保健环境的独特挑战采用细致入微的方法。
APCCC-JAPAN 2023 为日本高级前列腺癌管理方面的当前临床问题提供了有价值的见解。日本泌尿科医生和全球专家组之间的共识部分分歧突显了具体情况的方法的重要性。这项研究的结果为面临复杂挑战的医生提供了实用指导，应在高级前列腺癌的管理中用于指导决策。
